Premium
A phase II study of ibrutinib and short‐course fludarabine in previously untreated patients with chronic lymphocytic leukemia
Author(s) -
Pleyer Christopher,
Tian Xin,
Rampertaap Shakuntala,
Mu Rui,
Soto Susan,
Superata Jeanine,
Gaglione Erika,
Sun Clare,
Lotter Jennifer,
StetlerStevenson Maryalice,
Yuan Constance M.,
Maric Irina,
Pittaluga Stefania,
Rosenzweig Sergio,
Fleisher Thomas,
Wiestner Adrian,
Ahn Inhye E.
Publication year - 2020
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.25968
Subject(s) - ibrutinib , chronic lymphocytic leukemia , fludarabine , medicine , chemoimmunotherapy , clinical endpoint , oncology , bruton's tyrosine kinase , discontinuation , minimal residual disease , leukemia , immunology , clinical trial , chemotherapy , tyrosine kinase , cyclophosphamide , receptor